profit from every $100 of sales.
$0$100
Veracyte
$25.11+4.36% today
-41.1% in 1 year
1-year low $24.001-year high $60.49
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $30.54 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Veracyte sold, what it kept, and what it did with the cash.
Sales went from $297 million in 2022 to $517 million in 2025, with $66.4 million of profit last year.
SalesProfit
Veracyte vs. similar companies
Veracyte grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Veracyte | 30.5× · Expensive | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Veracyte's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 297 | 361 | 446 | 517 | |
| 176 | 230 | 298 | 363 | |
| -35 | -17 | 20 | 78 | |
| -10 | -49 | 49 | 90 | |
| -37 | -74 | 24 | 66 | |
| -0.51 | -1.02 | 0.31 | 0.82 | |
| 59.2% | 63.6% | 66.9% | 70.1% | |
| -11.9% | -4.8% | 4.4% | 15.1% | |
| -12.3% | -20.6% | 5.4% | 12.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,156 | 1,115 | 1,300 | 1,406 |
| Cash | 154 | 216 | 239 | 363 |
| Total debt | 15 | 13 | 51 | 40 |
| Total liabilities | 81 | 71 | 124 | 96 |
| 1,075 | 1,044 | 1,176 | 1,310 | |
| 72 | 73 | 78 | 81 | |
| -2.6% | -5.7% | 1.7% | 4.0% | |
| -3.4% | -7.1% | 2.1% | 5.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 8 | 44 | 75 | 136 | |
| 9 | 10 | 11 | 10 | |
| -1 | 34 | 64 | 127 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 27 | 33 | 36 | 44 |
Valuation
- 30.5×
- 15.1×
- –
- 2.3×
- 3.9×
- 16.0×
- 19.0×
- 6.2%
- 3.3%
- 0.0%
Profitability
- 70.1%
- 15.1%
- 12.8%
- 19.6%
- 4.7%
- -2.1%
- 6.9%
- 6.1%
- 4.9%
- 14.8%
Growth
- +20.4%
- –
- +98.5%
- –
- +3.7%
Financial health
- -2.1×
- 0.03
- 2.7%
- –
- 9.31
- 9.31
- 0.38
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 47%of 958
Top 34%of 889
Bottom 42%of 601
Top 28%of 890
Top 17%of 987
What analysts expect
- Average price target
- $44.50
- Range
- $37.00 – $50.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | 0.52 | 0.34 | +52.9% |
| Feb 25, 2026 | 0.53 | 0.41 | +29.8% |
| Nov 4, 2025 | 0.51 | 0.32 | +59.4% |
| Aug 6, 2025 | 0.44 | 0.31 | +41.9% |
| May 7, 2025 | 0.31 | 0.20 | +55.0% |
| Feb 24, 2025 | 0.36 | 0.10 | +260.0% |
| Nov 6, 2024 | 0.19 | 0.03 | +603.7% |
| Aug 6, 2024 | 0.30 | 0.05 | +530.8% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
47No pass
Benjamin Graham
46No pass
Philip Fisher
61Pass
Peter Lynch
84Pass
Joel Greenblatt
12No pass
Charlie Munger
47No pass
Terry Smith
54No pass
Questions about Veracyte
Is Veracyte a good stock to buy?
A solid business, but the price is high. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Veracyte AI analysis
What does Veracyte do?
Veracyte, Inc. operates as a diagnostics company worldwide. It is in Biotechnology, based in South San Francisco, CA, United States, with 755 employees.
Does Veracyte pay a dividend?
No. Veracyte does not pay a dividend at the moment.
Is Veracyte stock halal?
Yes. Veracyte passes our halal screen: its business is permitted and its debt is 2% of its market value, under the 30% limit. How we check
How has Veracyte stock done over the past year?
Down 41.1% over the past twelve months, to $25.11. It traded between $24.00 and $60.49 and is 58.5% below its high.
Who are Veracyte's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Veracyte's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.